Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
Cancer Medicine · 2024-04 · 13 (7)
DOI: 10.1002/cam4.7174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 15.04.2024. Verfasst von Jiyun Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Lung Cancer Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Objective
KINDLE‐Korea is part of a real‐world KINDLE study that aimed to characterize the treatment patterns and clinical outcomes of patients with stage III non‐small cell lung cancer (NSCLC). Materials and Methods The KINDLE was an international real‐world study that explores patient and disease characteristics, treatment patterns, and survival outcomes. The KINDLE‐Korea included stage III NSCLC patients diagnosed between January 2013 and December 2017.
Results
A total of 461 patients were enrolled. The median age was 66 years (range: 24–87). Most patients were men (75.7%) with a history of smoking (74.0%), stage IIIA NSCLC (69.2%), and unresectable disease (52.9%). A total of 24.3% had activating EGFR mutation and 62.2% were positive for PDL1 expression. Broadly categorized, 44.6% of the patients received chemoradiation (CRT)‐based therapy, 35.1% underwent surgery, and 20.3% received palliative therapies as initial treatment. The most commonly adopted approaches for patients with stage IIIA and IIIB disease were surgery and CRT, respectively. The median PFS was 15.2 months and OS was 66.7 months. Age >65 years, adenocarcinoma histology, and surgery as the initial treatment were significantly associated with longer OS.
Conclusion
This study revealed the heterogeneity of treatment patterns and survival outcomes in patients with stage III NSCLC before durvalumab consolidation came into clinical practice. There is an unmet need for patients who are not eligible for surgery as an initial therapy. Novel therapeutic approaches are highly warranted to improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lung Cancer Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
- Department of Medical Oncology, Gachon University Gil Medical Center, Incheon, Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Center for Lung Cancer, National Cancer Center, Research Institute and Hospital, Goyang, Korea.
- Department of Hematology-Oncology, Inje University Haeundae Paik Hospital, Busan, Korea.
- Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
ORCID-Profile: Sang-We Kim, Byoung Chul Cho
Förderung
- AstraZeneca
Zitieren
APA
Lee, J., Ahn, H. K., Kim, S. W., Han, J. Y., Lee, S. S., Park, H. S., Lee, H. W., Kim, J. H., Cho, E., Huggenberger, R., & Cho, B. C. (2024). Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study. Cancer Medicine, 13(7). https://doi.org/10.1002/cam4.7174
Vancouver
Lee J, Ahn HK, Kim SW, Han JY, Lee SS, Park HS, et al. Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study. Cancer Medicine. 2024;13(7). doi:10.1002/cam4.7174
BibTeX
@article{Lee2024,
author = {Lee, Jiyun and Ahn, Hee Kyung and Kim, Sang-We and Han, Ji-Youn and Lee, Sung Sook and Park, Hyung Soon and Lee, Hyun Woo and Kim, Joo-Hang and Cho, Eunhan and Huggenberger, Reto and Cho, Byoung Chul},
title = {Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {7},
doi = {10.1002/cam4.7174}
}
EUVIMED